STAT11d
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
STAT12d
Pharmalittle: We’re reading about lower-priced Zepbound vials, monkey shipments from Cambodia, and more
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
FiercePharma1d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
JD Supra26d
FDA Announced Removal of Tirzepatide from the Drug Shortage List
This order relates to certain FDA-approved Mounjaro and Zepbound products. The Mounjaro products are pre-filled single-dose pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL ...
Reuters12d
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...
phillyvoice.com7d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound ... offering about a 10% to 20% risk reduction for these conditions.